Erick Lucera Sells 1,448 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) CFO Erick Lucera sold 1,448 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $18.36, for a total transaction of $26,585.28. Following the completion of the transaction, the chief financial officer directly owned 123,925 shares in the company, valued at approximately $2,275,263. This represents a 1.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dyne Therapeutics Trading Down 5.4%

NASDAQ:DYN opened at $17.29 on Friday. Dyne Therapeutics, Inc. has a 12 month low of $8.06 and a 12 month high of $25.00. The firm has a market cap of $2.86 billion, a price-to-earnings ratio of -5.37 and a beta of 1.08. The company has a quick ratio of 22.25, a current ratio of 19.92 and a debt-to-equity ratio of 0.17. The company’s 50 day moving average is $18.34 and its 200-day moving average is $18.63.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter in the prior year, the business posted ($1.05) earnings per share. Equities analysts anticipate that Dyne Therapeutics, Inc. will post -2.99 EPS for the current year.

Hedge Funds Weigh In On Dyne Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of DYN. JPMorgan Chase & Co. raised its stake in shares of Dyne Therapeutics by 9.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,365,245 shares of the company’s stock valued at $42,570,000 after buying an additional 278,466 shares in the last quarter. Aberdeen Group plc boosted its position in shares of Dyne Therapeutics by 15.0% during the 3rd quarter. Aberdeen Group plc now owns 556,733 shares of the company’s stock valued at $7,043,000 after acquiring an additional 72,770 shares in the last quarter. Vanguard Group Inc. increased its stake in Dyne Therapeutics by 27.6% in the third quarter. Vanguard Group Inc. now owns 9,760,414 shares of the company’s stock valued at $123,469,000 after acquiring an additional 2,109,257 shares during the period. SG Americas Securities LLC bought a new stake in Dyne Therapeutics in the fourth quarter valued at about $5,191,000. Finally, Rafferty Asset Management LLC raised its position in Dyne Therapeutics by 93.4% in the third quarter. Rafferty Asset Management LLC now owns 213,211 shares of the company’s stock worth $2,697,000 after purchasing an additional 102,963 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Key Headlines Impacting Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $50 price target on Dyne Therapeutics while raising several earnings estimates, suggesting analysts remain confident in the company’s longer-term prospects.
• Positive Sentiment: Lifesci Capital also lifted its earnings forecasts for Dyne Therapeutics across multiple periods, pointing to improved expectations for future results.
• Neutral Sentiment: Dyne Therapeutics’ average brokerage rating remains Moderate Buy, indicating Wall Street sentiment is still constructive overall. Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Moderate Buy” by Brokerages
• Neutral Sentiment: The company recently reported a quarterly loss that was slightly better than expected, which is supportive but not a major catalyst on its own.
• Negative Sentiment: CEO John Cox, CFO Erick Lucera, and insider Douglas Kerr each sold shares this week. The filings say the sales were tied to tax withholding on equity vesting, but insider selling can still weigh on investor sentiment.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Evercore set a $33.00 target price on shares of Dyne Therapeutics in a research report on Friday. JPMorgan Chase & Co. dropped their target price on shares of Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Wall Street Zen raised shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, Morgan Stanley dropped their target price on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research report on Monday, March 2nd. Three research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $35.00.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.